RxSight price target lowered to $28 from $33 at Stifel

Stifel lowered the firm’s price target on RxSight (RXST) to $28 from $33 and keeps a Hold rating on the shares. While telling investors that RxSight has become a near-term “show-me” story, the analyst contends that recent underperformance “seemingly is market-driven” and believes the stock “warrants a fresh look.” Further downside in shares may be more-limited here, but the firm remains on the sidelines as U.S. competitive dynamics unfold and outside the U.S. expansion efforts commence, the analyst added.